Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 10:47AM ET
1.14
Dollar change
+0.07
Percentage change
6.54
%
IndexRUT P/E- EPS (ttm)-1.44 Insider Own11.35% Shs Outstand166.79M Perf Week3.64%
Market Cap202.18M Forward P/E- EPS next Y-0.50 Insider Trans-22.96% Shs Float157.22M Perf Month148.37%
Income-249.51M PEG- EPS next Q-0.24 Inst Own49.38% Short Float6.19% Perf Quarter191.04%
Sales201.42M P/S1.00 EPS this Y-10.94% Inst Trans8.09% Short Ratio4.59 Perf Half Y23.91%
Book/sh0.76 P/B1.50 EPS next Y64.15% ROA-61.33% Short Interest9.73M Perf Year-62.62%
Cash/sh0.74 P/C1.53 EPS next 5Y- ROE-112.37% 52W Range0.29 - 3.09 Perf YTD109.83%
Dividend Est.- P/FCF- EPS past 5Y-12.22% ROI-146.86% 52W High-63.11% Beta1.35
Dividend TTM- Quick Ratio3.04 Sales past 5Y7.72% Gross Margin89.77% 52W Low291.62% ATR (14)0.15
Dividend Ex-Date- Current Ratio3.04 EPS Y/Y TTM-21.01% Oper. Margin-53.28% RSI (14)63.78 Volatility15.91% 20.27%
Employees478 Debt/Eq0.26 Sales Y/Y TTM79.75% Profit Margin-123.87% Recom1.88 Target Price3.17
Option/ShortYes / Yes LT Debt/Eq0.26 EPS Q/Q-74.81% Payout- Rel Volume2.06 Prev Close1.07
Sales Surprise0.41% EPS Surprise-85.01% Sales Q/Q-64.48% EarningsNov 01 AMC Avg Volume2.12M Price1.14
SMA2036.02% SMA5084.68% SMA20038.16% Trades Volume1,037,583 Change6.54%
Date Action Analyst Rating Change Price Target Change
Nov-03-23Downgrade RBC Capital Mkts Outperform → Sector Perform $6 → $2
Apr-28-23Downgrade BofA Securities Neutral → Underperform $5 → $1.50
Feb-27-23Upgrade Wedbush Neutral → Outperform $16
Jan-06-23Downgrade BofA Securities Buy → Neutral $8 → $5
Jun-13-22Resumed Wedbush Neutral $5
May-04-21Initiated RBC Capital Mkts Outperform $22
Jan-07-21Resumed Guggenheim Neutral $16
Jan-06-21Initiated Stifel Hold $16
Dec-16-20Resumed H.C. Wainwright Buy $25
Sep-08-20Initiated BofA Securities Buy $20
Feb-12-24 08:05AM
Feb-05-24 06:01PM
Nov-03-23 05:03PM
Nov-02-23 08:15AM
Nov-01-23 07:05PM
04:13PM Loading…
04:13PM
04:01PM
Oct-26-23 10:02AM
Oct-25-23 04:15PM
Oct-24-23 02:01AM
Sep-20-23 04:15PM
Aug-25-23 01:38PM
Aug-08-23 05:30PM
04:26PM
04:01PM
04:15PM Loading…
Aug-01-23 04:15PM
Jul-20-23 08:05AM
Jul-19-23 07:08AM
Jul-17-23 08:05AM
Jun-29-23 08:05AM
Jun-28-23 09:20AM
Jun-14-23 08:16AM
May-22-23 08:05AM
May-18-23 07:04AM
May-16-23 08:00AM
May-02-23 04:30PM
06:03AM
Apr-26-23 05:28PM
Apr-25-23 02:39PM
Apr-21-23 04:58AM
04:15PM Loading…
Apr-19-23 04:15PM
Apr-17-23 07:38AM
Apr-16-23 06:30AM
Mar-23-23 06:09AM
Mar-21-23 09:35AM
Mar-20-23 12:25PM
Mar-10-23 09:35AM
Feb-25-23 08:26AM
Feb-23-23 05:36PM
11:57AM
Feb-22-23 05:25PM
04:01PM
03:01PM
09:35AM
Feb-21-23 09:01AM
Feb-16-23 10:01AM
Feb-13-23 09:55AM
Feb-10-23 11:01AM
Jan-30-23 07:10PM
Dec-06-22 06:02AM
Nov-09-22 05:31AM
Nov-03-22 05:55PM
04:01PM
Oct-27-22 04:15PM
Oct-14-22 09:49AM
Oct-12-22 08:55AM
03:01AM
Sep-23-22 12:02PM
Sep-18-22 09:11AM
Aug-30-22 08:50AM
06:00AM
Aug-29-22 09:55AM
Aug-12-22 09:55AM
Aug-04-22 05:45PM
04:01PM
Jul-28-22 04:15PM
Jul-21-22 08:05AM
Jul-18-22 09:21AM
Jun-07-22 08:55AM
Jun-01-22 04:30PM
May-08-22 08:09AM
May-05-22 05:45PM
04:01PM
May-04-22 06:35PM
May-02-22 04:30PM
Apr-28-22 04:15PM
Apr-21-22 04:30PM
Apr-11-22 08:59AM
Mar-30-22 06:40AM
Mar-29-22 08:05AM
Feb-28-22 05:00PM
Feb-24-22 06:20PM
04:01PM
Feb-17-22 04:30PM
Feb-08-22 11:32AM
06:52AM
Feb-07-22 06:00PM
Jan-21-22 05:38PM
Jan-13-22 01:38PM
Jan-06-22 08:00AM
Jan-04-22 05:00PM
Dec-20-21 05:29PM
Dec-13-21 10:54AM
Dec-12-21 04:30PM
09:00AM
Dec-10-21 09:34AM
Nov-22-21 07:00AM
Nov-18-21 05:54PM
Nov-09-21 08:30AM
Nov-08-21 10:13AM
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOGEN INC.10% OwnerSep 26Sale0.506,000,0003,000,00017,652,466Sep 28 05:30 PM